Literature DB >> 9935109

Administration of progesterone before oocyte retrieval negatively affects the implantation rate.

S H Sohn1, A S Penzias, A M Emmi, A K Dubey, L C Layman, R H Reindollar, A H DeCherney.   

Abstract

OBJECTIVE: To compare the efficacy of two clinically accepted methods of progesterone supplementation during IVF.
DESIGN: Prospective randomized trial.
SETTING: A university-based IVF program. PATIENT(S): Three hundred fourteen stimulated IVF cycles between January 1993 and October 1994. INTERVENTION(S): Patients were assigned to one of two luteal phase progesterone regimens by a random permuted block design. In protocol A, 12.5 mg of IM progesterone was given 12 hours before oocyte retrieval; in protocol B, 25 mg of IM progesterone was given on the day of oocyte retrieval. MAIN OUTCOME MEASURE(S): Clinical pregnancy. RESULT(S): Patient demographic characteristics, including age, diagnosis, number of oocytes retrieved and fertilized, and number of embryos transferred, were not different between the two groups. There was no difference in the rate of cycle cancellation between the groups. One hundred forty ETs were performed in patients assigned to protocol A and 142 in patients assigned to protocol B. The clinical pregnancy rate in group A was 12.9% compared with 24.6% in group B. CONCLUSION(S): The administration of progesterone before oocyte retrieval is associated with a lower pregnancy rate than the administration of progesterone after oocyte retrieval.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935109     DOI: 10.1016/s0015-0282(98)00404-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

1.  Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates.

Authors:  Ricardo Baruffi; Ana Lucia Mauri; Claudia Guilhermino Petersen; Valéria Felipe; José Gonçalves Franco
Journal:  J Assist Reprod Genet       Date:  2003-12       Impact factor: 3.412

Review 2.  Timing luteal support in assisted reproductive technology: a systematic review.

Authors:  Matthew T Connell; Jennifer M Szatkowski; Nancy Terry; Alan H DeCherney; Anthony M Propst; Micah J Hill
Journal:  Fertil Steril       Date:  2015-01-29       Impact factor: 7.329

Review 3.  The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage.

Authors:  Hisham Arab; Ahmed Jaber Alharbi; Ayman Oraif; Emad Sagr; Hana Al Madani; Hassan Abduljabbar; Osama Sadeak Bajouh; Yaser Faden; Yasser Sabr
Journal:  Int J Womens Health       Date:  2019-11-07

4.  A 10-year follow-up on the practice of luteal phase support using worldwide web-based surveys.

Authors:  Gon Shoham; Milton Leong; Ariel Weissman
Journal:  Reprod Biol Endocrinol       Date:  2021-01-26       Impact factor: 5.211

5.  Progesterone supplementation in natural cycles improves live birth rates after embryo transfer of frozen-thawed embryos-a randomized controlled trial.

Authors:  K Wånggren; M Dahlgren Granbom; S I Iliadis; J Gudmundsson; A Stavreus-Evers
Journal:  Hum Reprod       Date:  2022-09-30       Impact factor: 6.353

Review 6.  The effects of progesterone on oocyte maturation and embryo development.

Authors:  Mojdeh Salehnia; Saeed Zavareh
Journal:  Int J Fertil Steril       Date:  2013-07-31

Review 7.  Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue?

Authors:  Stefano Palomba; Susanna Santagni; Giovanni Battista La Sala
Journal:  J Ovarian Res       Date:  2015-11-19       Impact factor: 4.234

8.  Luteal Phase Support in IVF: Comparison Between Evidence-Based Medicine and Real-Life Practices.

Authors:  Federica Di Guardo; Habib Midassi; Annalisa Racca; Herman Tournaye; Michel De Vos; Christophe Blockeel
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-18       Impact factor: 5.555

Review 9.  Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review.

Authors:  Jing Zhao; Jie Hao; Yanping Li
Journal:  Reprod Health       Date:  2022-01-22       Impact factor: 3.223

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.